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Dear Sir,
A 46-year-old male farmer presented with anaemia (63 g/l),
thrombocytopenia (22×109/l) and leukocytosis (26.6×109/l;
with 34% blasts). The bone marrow showed a 90%
infiltration with myelomonocytic blasts and abnormal
eosinophils. Molecular and cytogenetic analysis documen-
ted the pericentric inversion of chromosome 16, inv(16)
(p13q22). A diagnosis of AML-M4Eo was made, and a
treatment with cytarabine and idarubicin was initiated.
Eighteen days after the onset of chemotherapy, the
patient developed a single necrotic lesion at his right lower
arm doubling daily in size (Fig. 1, upper panel). At this time,
the patient was under cefipime for 3 days. Surgical resection
revealed extensive necrotic debris of the entire dermis
extending to the subdermal tissue. Blood vessels were filled
with inflammatory cells, and extensive angioinvasion was
observed with fungal elements (Fig. 1, middle panel). A
fungal-specific stain such as Gomori methenamine silver
easily demonstrated the fungal elements (Fig. 1, lower
panel). Further characterization identified the fungal ele-
ments to be Mucorales species, one of the two groups of
Zygomycetes.
Cultures from blood, bone marrow, urine and bronchi-
alveolar fluid showed no evidence of fungi. Computed
tomography (CT) scan revealed no fungal infection. A
treatment with amphotericin B was started and changed to
the liposomal preparation due to impaired renal function.
The bone marrow showed a complete remission from
leukaemia at day 19. No inv(16) transcripts were detectable
after two cycles. Antifungal therapy was continued through-
out chemotherapy cycles two and three, and no evidence of
relapsing fungal infection was observed.
The Zygomycetes represent relatively uncommon iso-
lates in the clinical laboratory. Human zygomycosis caused
by the Mucorales generally occurs in immunocom-
promised hosts as opportunistic infections. Therapy for
zygomycosis requires surgical intervention, antifungal
therapy and medical management of the underlying con-
dition. Interestingly, the patient presented here received a
blood transfusion at the day of hospitalization, and the
cutaneous zygomycosis developed at this particular cath-
eter insertion site. The breakdown in the integrity of the
cutaneous barrier, therefore, has to be assumed as the
predisposing event together with the immunosuppression
mediated by the outbreak of acute leukaemia and the onset
of chemotherapy.
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Fig. 1 (upper panel) Single necrotic lesion at the right lower arm of
the patient.(middle panel) Extensive necrotic debris of the entire
dermis extending to the subdermal tissue.(lower panel) Gomori
methenamine silver stain demonstrated the fungal elements
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